ID   BT 239
AC   CVCL_WW54
SY   BT239
DR   PharmacoDB; BT239_129_2019
DR   Wikidata; Q93432609
RX   PubMed=25184684;
RX   PubMed=27723727;
CC   Characteristics: Low-passage-number culture.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 19-12-24; Version: 8
//
RX   PubMed=25184684; DOI=10.1371/journal.pone.0106694; PMCID=PMC4153667;
RA   Holmberg Olausson K., Maire C.L., Haidar S., Ling J., Learner E.,
RA   Nister M., Ligon K.L.;
RT   "Prominin-1 (CD133) defines both stem and non-stem cell populations in
RT   CNS development and gliomas.";
RL   PLoS ONE 9:E106694-E106694(2014).
//
RX   PubMed=27723727; DOI=10.1038/nbt.3697; PMCID=PMC5142231;
RA   Stevens M.M., Maire C.L., Chou N., Murakami M.A., Knoff D.S.,
RA   Kikuchi Y., Kimmerling R.J., Liu H.-Y., Haidar S., Calistri N.L.,
RA   Cermak N., Olcum S., Cordero N.A., Idbaih A., Wen P.Y.-C.,
RA   Weinstock D.M., Ligon K.L., Manalis S.R.;
RT   "Drug sensitivity of single cancer cells is predicted by changes in
RT   mass accumulation rate.";
RL   Nat. Biotechnol. 34:1161-1167(2016).
//